




RealRate

PHARMACEUTICAL 2023

Benitec Biopharma Inc
Rank 429 of 471



The relative strengths and weaknesses of Benitec Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.3% points. The greatest weakness of Benitec Biopharma Inc is the variable Assets, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 163% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	4,820	Assets	5,973
Cost of Goods Sold	0	Liabilities	3,091
Intangible Assets	0	Expenses	17,927
Liabilities, Current	2,532	Revenues	73
Liabilities, Non-Current	559	Stockholders Equity	2,882
Other Assets	931	Net Income	-18,208
Other Compr. Net Income	210	Comprehensive Net Income	-18,103
Other Expenses	9.0	BaseVar	13,814
Other Liabilities	0	ECR before LimitedLiability	-261%
Other Net Income	-354	Economic Capital Ratio	82%
Other Revenues	73		
Property and Equipment	222		
Research and Development	11,272		
Selling, General and Administrative Expense	6,646		